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intravenous immunoglobulin gamma prepaa b s t r a c t
Coagulation factors (II, VII, IX, X, and particularly XIa) remaining in high concentrations in intravenous
immunoglobulin (IVIG) preparations can form thrombi, causing thromboembolic events, and in serious
cases, result in death. Therefore, manufacturers of biological products must investigate the ability of their
production processes to remove procoagulant activities. Previously, we were able to remove coagulation
factors II, VII, IX, and X from our IVIG preparation through ethanol precipitation, but factor XIa, which
plays an important role in thrombosis, remained in the intermediate products. Here, we used a chro-
matographic process using a new resin that binds with high capacity to IgG and removes procoagulant
activities. The procoagulant activities were reduced to low levels as determined by the thrombin gen-
eration assay: <1.56 mIU/mL, chromogenic FXIa assay: <0.16 mIU/mL, non-activated partial thrombo-
plastin time (NaPTT): >250 s, FXI/FXIa ELISA: <0.31 ng/mL. Even after spiking with FXIa at a
concentration 32.5 times higher than the concentration in normal specimens, the procoagulant activities
were below the detection limit (<0.31 ng/mL). These results demonstrate the ability of our
manufacturing process to remove procoagulant activities to below the detection limit (except by NaPTT),
suggesting a reduced risk of thromboembolic events that maybe potentially caused by our IVIG
preparation.
© 2016 The Author(s). Published by Elsevier Ltd on behalf of International Alliance for Biological
Standardization. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).1. Introduction
Intravenous immunoglobulin G (IVIG) has been used for treating
various immunological deﬁciencies and autoimmune disorders.
Different manufacturers of IVIG use different manufacturing pro-
cesses, resulting in differences in the ﬁnal product composition
[1e5].
In general, treatments involving IVIG use puriﬁed IgG from
human plasma, which ensures high safety of the preparations. Such
treatments have been widely used until now, except in rare cases,G; TGA, Thrombin generation
time; PVDF, Polyvinylidene
yme-linked immunosorbent
Kim), jhhan551@skku.edu
er Ltd on behalf of International Al
y-nc-nd/4.0/).
et al., A new manufacturing
rations, Biologicals (2016), htsuch as in patients with IgA deﬁciency [6]. However, recently,
thromboembolic events were found to have occurred in a patient
who had received a high dose of IVIG. Thromboembolic events are
induced when the coagulation factor XIa (FXIa) remaining in the
IVIG preparation (as a result of imperfect removal in the
manufacturing process) activates the coagulation cascade in the
blood of the recipient [7,8].
Consequently, the revised European pharmacopeia now rec-
ommends that manufacturers include a quality check to ensure the
removal of thrombosis-generating agents (coagulation factors and
their zymogens) in IVIG manufacturing processes or submit evi-
dences to indicate that the product does not induce zymogen
activation [9].
Typically, the ethanol precipitation method developed in the
1940s is used to separate IgG from plasma [10,11]. However, it is
difﬁcult to completely isolate and purify IgG from the FXIa only
through ethanol precipitation due to the high isoelectric point (pI
8.9e9.1) of FXIa [12]. Therefore, an additional puriﬁcation process isliance for Biological Standardization. This is an open access article under the CC BY-
process to remove thrombogenic factors (II, VII, IX, X, and XI) from
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Effective removal of FXIa is a very important aspect in the
manufacture of safe IVIG preparations. During the manufacturing
process, this step is conducted using various methods such as
caprylic acid precipitation and membrane chromatography [13,14].
However, in the case of preparations with high concentrations of
IVIG (e.g., blood preparations), the use of a membrane ﬁlter reduces
the overall yield or increases the cost of materials required for the
process; thus, it is difﬁcult to introduce this step into the
manufacturing process. It is therefore necessary to develop a
manufacturing process that can provide sufﬁcient yield and can
maximize the safety of the preparations without increasing the
manufacturing time.
GC5101B is a high-purity pharmaceutical IVIG preparation
manufactured through cold ethanol fractionation and chromatog-
raphy. In this study, we developed a new process for reducing the
content of FXIa in IVIG preparations to levels below the detection
limits to ensure the safety of GC5101B. Furthermore, since blood
products are generally derived from plasma from over 1000 donors,
there are differences in protein quantity and composition
depending on the country or state of the donor. Therefore, we
further spiked our samples with additional coagulation factor XIa,
in amounts exceeding any variability that may be caused due to
sample differences, and were able to still successfully remove XIa,
thus verifying the robustness of our manufacturing process.
2. Materials and methods
2.1. Materials
The intermediate and ﬁnal puriﬁcation products of GC5101B
from the original manufacturing process were provided by Green
Cross Corp. (Korea), and the standard coagulation-factor materials
for the spiking study were purchased from HTI (Hematologic
Technologies Inc., USA). For the thrombin generation assay (TGA),
the WHO reference reagent NIBSC (1st international reference re-
agent for activated blood coagulation factor XI (FXIa), HumanNIBSC
code: 11/236) was used; for the non-activated prothrombin time
test (NaPTT) assay, NIBSC's factor XIa was used. For the chromo-
genic FXIa assay, a biophen factor XIa kit (Chromogenix, UK) was
used.
2.2. Study design
During the manufacturing process, cryo-poor pooled plasma
was used as a starting material and a paste containing Fraction
I þ IIþ III, a supernatant containing Fraction I þ III, and a Fraction II
paste was produced through cold ethanol fractionation. The start-
ing material for the manufacturing process for GC5101B was the
Fraction II paste obtained by cold ethanol precipitation. This Frac-
tion II paste was dissolved into 4-fold volume of 0.6% sodium
chloride solution at below 10 C. Next, the pH was adjusted to 5.0,
which was followed by clarifying depth ﬁltration (nominal size:
0.1 mm). 1 M sodium acetate was added to the diaﬁltrated IgG so-
lution to a ﬁnal concentration of 5.0 mM; the pH was then adjusted
to 6.0 and the solution was subjected to AEX chromatography. The
unbound fraction was collected and its pH was adjusted to 5.0
before subjecting it to the solvent/detergent virus inactivation
process. Tri(n-butyl)-phosphate (TNBP) and Polysorbate 80 (Tween
80) were added at concentrations of 0.3% and 1.0%, respectively, and
the mixture was then incubated at 25 C for 8 h. To bring the ﬁnal
concentration to 20 mM, 1 M sodium acetate was added to the
ﬁltrate, and the ﬁltrate was subjected to CEX chromatography to
absorb IgG. Another clarifying depth ﬁltration was then performed
at the same pH just before CEX chromatography. After CEXPlease cite this article in press as: Park DH, et al., A new manufacturing
intravenous immunoglobulin gamma preparations, Biologicals (2016), htchromatography, the ﬁltrate was washed with equilibrium buffer
(20mM sodium acetate, pH 5.0) and then elutedwith elution buffer
(20 mM sodium acetate with 0.5 M sodium chloride, pH 4.5) to
acquire IgG; The salt content was eliminated by Ultra/Dia-ﬁltration.
A nanoﬁlter (Ultipor®VF DV 20, Pall Lifescience, Switzerland) was
used to eliminate viruses, and stabilizers were applied. Finally, after
sterile ﬁltration, the ﬁnished product was obtained. We then
determined the procoagulant activities from each of the interme-
diate and ﬁnished products.
2.3. Detection of FX/FXla
FXI/FXIa content in the intermediate products of
GC5101BdFraction Iþ IIþ III Paste, Fraction Iþ III supernatant, and
Fraction II Pastedwas analyzed using western blot and ELISA, and
its procoagulant activity was analyzed using TGA. The procoagulant
activity of the ﬁnal product was measured using TGA, chromogenic
FXIa assay, and NaPTT assay. Each method was veriﬁed based on
ICH Guideline Q2 (R1) [15] and was used in the analysis of the in-
termediate and ﬁnal products.
2.4. TGA
TGA was conducted in accordance with “CBER Ig-Thrombin
Generation Test Protocol (automated version)” [16]. There are two
methods for the determination of the potential risk of thrombo-
embolic events: Wessler test (in vivo) and TGA (in vitro). TGA is
known to be the most sensitive and reliable method for detecting
thrombogenic agents in plasma-derived preparations. To measure
FXIa contents, the test sample was treated with a mixture of 50 mL
Factor XI (FXI)-deﬁcient plasma (Hematologic Technologies Inc.,
USA), 2.5 mL tissue factor ((Dade Innovin®, USA), 2.5 mL phospho-
lipid (Rossix, Sweden) and 8.75 mL of CaCl2 (Sigma Aldrich, USA).
Activated thrombin in the test samples were measured by
analyzing the release of a ﬂuorophore from a ﬂuorogenic substrate
(Z-Gly-Gly-Arg-AMC, Bachem, Switzerland) with a kinetic ﬂuores-
cent reader (Inﬁnite F-500, Tecan, Switzerland; excitation wave-
length: 380 nm, emission wavelength: 430 nm) at 37 C. This value
was applied to the standard curve constructed with ﬂuorescence
measurements obtained for standard product (FXIa, NIBSC 11/236).
Undiluted IgG specimen, FXIa standard (FXIa, NIBSC 11/236) and
IVIG from normal production batches were used as controls. IVIG
samples, from a high or low procoagulant Ig lot, were selected to
measure reproducibility.
2.5. NaPTT assay
The NaPTT assay was performed to determine the coagulation
time as a means to measure the activities of coagulant factors. The
NaPTT assay was conducted according to Ph. Eur. 2.6.22 [17]. The
Fraction I þ II þ III paste was dissolved in sterile water (Water for
Injection, manufacturing site) at a 1:5 ratio for 5e7 h, followed by
ﬁltration using a syringe ﬁlter. The Fraction II pastewas dissolved in
0.6% sodium chloride at a 1:4 ratio for 1 h. Cryo-poor plasma, dis-
solved Fraction I þ II þ III Paste, Fraction I þ III supernatant, and
dissolved Fraction II Paste were further diluted 10 times with Tris-
albumin buffer. Citrated plasma was used as a control. A series of
polystyrene tubes were placed in a water-bath at 37 C and 0.1 mL
of platelet-poor plasma substitute R was added to each tube. 0.1 mL
of the diluted samples or 0.1 mL of the buffer (control tube) was
added to the tubes. Then, 0.1 mL of a 3.7 g/L solution of calcium
chloride R (previously warmed to 37 C) was added immediately to
all the tubes. Clotting time was measured using a manual coagu-
lator (Sigma KC4 coagulator, Amelung, Germany) within 30 min of
adding the original dilution as the time that elapses between theprocess to remove thrombogenic factors (II, VII, IX, X, and XI) from
tp://dx.doi.org/10.1016/j.biologicals.2016.11.002
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clot. This test is not valid unless the coagulation time measured for
the control tube is 200 se300 s. We also measured the clotting time
using a ACL TOP 500 (Instrumentation Laboratory, USA).
2.6. Chromogenic FXIa assay
FXIa activity was measured using the ROX FACTOR XIa test kit
(Rossix, Sweden). FIX, FVIII, and calcium chloride were added to the
specimen to activate FIX for conversion to FIXa. When the con-
version of FX to FXa was induced by activated FIXa, the activated
FXa hydrolyzed the substrate (Z-D-Arg-Gly-Arg-pNA) and pro-
duced a chromogenic product (p-nitroalanine), which was
measured at a wavelength of 405 nm (reference wavelength:
490 nm). FXIa activity was then measured by comparisonwith that
of the standard solution (biophen factor XIa kit, Chromogenix, UK).
2.7. Immunoblotting
For immunoblotting, each sample was subjected to SDS-PAGE
and then electroblotted onto a polyvinylidene diﬂuoride (PVDF)
membrane by semi-dry transfer (Bio-Rad, USA). The membrane
was then blocked for 1 h and incubated overnight at 4 C with the
indicated primary antibody (Anti-human Factor XI primary poly-
clonal antibody, Innovative Research, USA), followed by incubation
with horseradish peroxidase-conjugated secondary antibodies for
1 h (Innovative Research, USA). The signals were then detected
using chemiluminescence reagents (Intron, USA).
3. Results
When each intermediate product was analyzed using ELISA, the
percentages of FXIa remaining were 74.4%, 5.8%, and 5.2% in the
Fraction I þ IIþ III paste, Fraction I þ III supernatant, and Fraction II
paste, respectively. The comparison of these percentages to those in
the cryo-poor pooled plasma is shown in Fig. 1. The results show
that 5.2% FXIa was remaining, which indicates that cold ethanol
fractionation alone could not remove FXIa completely.
The procoagulant activity of the intermediate products in each
process was determined using ELISA (for the amount of FXI/FXIa),
TGA, chromogenic FXIa assay, Prekallikrein activator (PKA) test,Fig. 1. FXIa remaining after cold ethanol fractionation. The FXIa content for each
process was calculated using the step residual ratio. 1. Cryo-poor plasma (statistical
results of 3 batches, mean ± SD): 100%, 2. Fraction I þ II þ III paste: 74.4 ± 3.7, 3.
Fraction I þ III supernatant: 5.8 ± 2.7, 4. Fraction II paste: 5.2 ± 2.1 Results from 3
consecutive batches are shown; all samples were measured at least in duplicate.
Please cite this article in press as: Park DH, et al., A new manufacturing
intravenous immunoglobulin gamma preparations, Biologicals (2016), htkallikrein activity measurement, and NaPTT assay. The results
indicate that cold ethanol fractionation process removed most of
the procoagulant activity, but not all of it (Fig. 2). As shown in Fig. 2,
cryo-poor plasma showed increased procoagulant activity by the
TGA, chromogenic FXIa assay, PKA test, Kallikrein activity test, and
NaPTT; the FXI/FXIa content measured by ELISA, however, showed
a contrasting result.
We conﬁrmed that coagulation factor VII was removed using
supernatant removal from the Fraction I þ II þ III, and that FII, FIX,
and FX were removed using precipitation removal from Fraction
I þ III. However, FXI/FXIa was not removed completely, leaving
some amount in the Fraction II paste (Fig. 3).
We then attempted to improve the product safety of GC5101B by
including anion exchange and cation exchange chromatographic
processes during the manufacturing for the removal of plasma-
derived impurities and procoagulant activity remaining in the
Fraction II paste and by adding the virus inactivation (S/D treat-
ment) and virus removal (nano-ﬁltration) processes (Fig. 4).
Anion exchange chromatography was effective in removing
plasma-derived impurities and PKA, but could not remove FXIa
(Fraction II paste: 13.0 ng/mL, pre-CEX chromatography: 10.3 ng/
mL). Coagulation factor XIa was then removed using CEX chroma-
tography. The ceramic-based resin (CM Ceramic Hyper D Sorbent,
Pall Lifescience) used in CEX chromatography has 1.5 times higher
binding capacity compared to commonly used resins in protein
puriﬁcation. This allowed the column to be more compact to efﬁ-
ciently reduce the amount of buffer required and the time required
for the production process (binding capacity: 100.0 g/L of resin or
higher). In addition, with a loading of pH 5.0, the elution pH was
adjusted to 4.5 and Ultra/Diaﬁltration was conducted at the same
time as IgG elution to eliminate the risk of reversible polymeriza-
tion due to salt (Table 1). Samples were analyzed by western blot
before and after CEX chromatography, and the results showed that
FXI/FXIa was reduced to an undetectable level (Fig. 3). FXIa absor-
bed with IgG was not eluted under high salt concentrations (2.0 M)
and was removed in 6.0 M guanidine hydrochloride CIP. Consid-
ering that the elution salt level is 500 mM in CEX chromatography,
there is no risk of introducing FXIa after CEX chromatography
process.
Since IVIG uses various types of plasma samples as the starting
material, there can be a variation in the content of FXIa. Therefore, a
spiking study was conducted to evaluate the removal rate of FXIa
during CEX chromatography. In general, the concentration of FXIa
in plasma is 4e6 mg/mL [8,18]. The manufacturing process for
GC5101B could remove approximately 95% of the FXIa through cold
ethanol fractionation. However, since the amount of FXIa varies
depending on the plasma type, the effectiveness of the removal
process for various plasma types needs to be veriﬁed (in cases
where FXIa can be additionally introduced). Therefore, we per-
formed a spiking study to evaluate the FXIa removal capacity of our
new manufacturing process. The spiking study was conducted us-
ing FXIa at a concentration of 4.0 mg/mL (concentration in normal
plasma) and 21.0 mg/mL (concentration in cryopaste), which were
32.5 times and 169.9 times higher than the concentrations found in
normal samples (Fig. 5, Table 1).
The FXIa concentration in the specimen spiked with 32.5 and
169.9 times the concentration of FXIa as that present in a normal
specimen in a production process is shown in Table 1. In this study,
when the sample was spiked with FXIa at 32.5 times (4.0 mg/mL)
the concentration in normal specimens, the amount of FXI/FXIa
remaining after the removal process (post-CEX sample) was found
to be below the detection limits (ELISA). This observation
conﬁrmed that the manufacturing process could completely
remove FXIa from the pre-process specimen, even when it is pre-
sent at a concentration 30 times more than that in a normalprocess to remove thrombogenic factors (II, VII, IX, X, and XI) from
tp://dx.doi.org/10.1016/j.biologicals.2016.11.002
Fig. 2. Procoagulant activity, as determined by in-vitro assays performed during cold ethanol fractionation. Since each intermediate product has different IgG concentrations, the
results are shown relative to IgG level. Concentration of IgG (mean ± SD): 1. 7.2 ± 0.4 g/L, 2. 5.2 ± 0.2 g/L, 3. 3.8 ± 0.2 g/L, 4. 39.2 ± 2.3, 1. Cryo-poor plasma, 2. Fraction I þ II þ III
paste, 3. Fraction I þ III supernatant, and 4. Fraction II paste. 5. Normal citrated plasma for NaPTT. A. ELISA (statistical results of 3 batches, mean ± SD): 1. 478 ± 37.9, 2. 388.2 ± 25.5,
3. 43.1 ± 20.7, 4. 42.5 ± 19.8. B. TGA: 1. 0.4 ± 0.1, 2. 1243.9 ± 219.0, 3. 24.0 ± 15.4, 4. 249.6 ± 124.1. C. Chromogenic FXIa assay: 1. 0.6 ± 0.2, 2. 60.8 ± 17.2, 3. 1.9 ± 1.1, 4. 4.5 ± 2.2. D. PKA
test: 1. 69.3 ± 42.6, 2. 1110.4 ± 235.3, 3. 3.7 ± 2.1, 4. 11.7 ± 5.5. E. Kallikrein activity measurement: 1. 2.8 ± 0.2, 2. 3.9 ± 0.9, 3. 0.7 ± 0.2, 4. 0.3 ± 0.1. F. NaPTT: 1. 165.1 ± 5.0, 2.
135.8 ± 6.4, 3. 166.4 ± 4.2, 4. 174.9 ± 2.9, 5. 240.1 ± 7.5. Results from 3 consecutive batches are shown; all samples were measured at least in duplicate.
Fig. 3. Removal of coagulation factors (FII, FVII, FIX, FX, and FXIa) by cold ethanol fractionation and CEX chromatography. Loading amount is 5.0 mg of IgG and concentration of FXI/
FXIa calculated by ELISA: 1. Cryo-poor plasma (219.0 ng/mL), 2. Fraction I þ II þ III paste (183.0 ng/mL), 3. Fraction I þ III paste (14.0 ng/mL), 4. Fraction II paste (13.0 ng/mL), 5. Pre-
CEX chromatography (10.3 ng/mL), 6. Post-CEX chromatography (not detected). A. Image of the western blot with control (Non-reduced condition, 4e20% Tris-glycine gel, upper
arrow: IgG monomer, 150 kDa, lower arrow: IgG polymer), B. Band density of FXI/FXIa calculated using Prizm ver. 6.0.
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Fig. 4. Overall ﬂow chart of the manufacturing process for the IVIG preparation. 1) The
purpose was to eliminate thrombogenic impurities such as FII, FVII, FIX, FX, and FXIa.
In particular, FXIa was completely removed after CEX chromatography.
D.H. Park et al. / Biologicals xxx (2016) 1e8 5specimen. However, when the specimen was spiked with 21.0 mg/
mL of FXIa, a small amount of FXI/FXIa (2.93 ng/mL) remained in
the solution. Nevertheless, the residual ratio, based on which the
process efﬁciency is measured, was 0.01%, indicating that a very
small percentage of FXIa remained in the sample. Furthermore,
FXIa activity, as determined using the TGA, was also found to be
below the detection limits, thus suggesting that the potential risk of
thromboembolic events that may be caused by GC5101B prepared
using this new process would be very minor (Table 1).
Nine consecutive batches of GC5101B were produced on a
commercial scale using the new process, and the potential risk of
thromboembolic events was estimated by measuring the procoa-
gulant activity in the pharmaceutical GC5101B preparations. The
results of the TGA and chromogenic FXIa assays were below the
detection limits (<1.56 mIU/mL and <0.16 mIU/mL, respectively),Table 1
Evaluation of the reduction of FXIa contents and activity by the spiking test in cation ex
Process step Prot. conc. (g/L) Purity (%) Polymer contents (%) Pre-CEX w
ELISA a (mg
Pre-CEX 21.1 99.6 0.16 123.6
Post-CEX 10.4 99.8 0.12 <0.31
IgG recovery (%) 97.1
Residual ratio (%) N.C.c
All samples were measured at least in duplicate.
a ELISA: Enzyme-linked immunosorbent assay.
b TGA: Thrombin generation assay.
c N.C.: Not calculated.
d These concentrations are 32.5 times and 169.9 times higher than those in normal sp
Please cite this article in press as: Park DH, et al., A new manufacturing
intravenous immunoglobulin gamma preparations, Biologicals (2016), htand the coagulation time measured using the NaPTT assay was
>250 s in all the batches, thus conﬁrming that no procoagulant
activity existed in the ﬁnal product. Moreover, the standard devi-
ation between the batches was less than 5%, indicating that the
production process was robust (Table 2).4. Discussion
Among all thrombogenic factors, FXIa is known to play the
greatest role in causing thrombolytic events. Recently, a thrombo-
embolic event that occurred in a patient who had received a high
dose of IVIG was found to be induced by the FXIa remaining in the
pharmaceutical preparation used [7,8]. In this study, we established
a method to remove FXIa to undetectable levels (<0.31 ng/mL, as
determined by ELISA). This was accomplished by using CEX chro-
matography with a new resin with high binding capacities for IgG.
By adjusting the pH of the elution buffer to 4.5 and conducting
ultra/diaﬁltration, we maximally inhibited IgG polymerization to
establish a stable manufacturing process for GC5101B (IgG recov-
ery: 97.7 ± 2.2%, molecular distribution: pre-CEX polymer ratio
0.16 ± 0.04%, post-CEX polymer ratio 0.12 ± 0.05%, purity:
99.5 ± 0.1%) (Table 1). Thus, our method maximized the FXIa
removal efﬁciency during the manufacturing process of GC5101B.
Interestingly, both FXIa and PKA activities substantially increase
in Fraction I þ II þ III as compared to the cryo-poor plasma sample.
This is caused due to the activation of FXI to FXIa during the pre-
cipitation and ﬁltration step [19e21]. Further, PKA, known as
Hageman factor or FXIIa, is a type of serine protease that converts
Prekallikrein to Kallikrein, which also activates FXI, a Prekallikrein
homologue, in the upper level of the intrinsic pathway, or FVII in
the extrinsic pathway [22e25]. PKA activation in the plasma is
inhibited by anti-thrombin III, C1 inhibitor, a1-antitrypsin, a2-
antitrypsin, protease Nexin2, Kunitz-type protease inhibitor
[26,27], but during Fraction I þ II þ III precipitation and ﬁltration,
inhibitors such as anti-thrombin III are removed as supernatants,
thus allowing PKA activation. The increased levels of PKA activation
could be not only due to activated Prekallikrein, but could also be
due to activated FXI.
Furthermore, because the amount of FXIa can vary according to
the plasma source as a natural result of blood preparation, we also
evaluated the robustness of the process through a spiking study.
With this spiking assay, we showed that the high binding capacity
of resin (>100.0 g/L) further increased the production efﬁciency.
The spiking study including cation exchange chromatography was
conducted using 32.5 and 169.9 times the concentration of FXIa as
that present in normal specimens, and the results were analyzed
using ELISA and TGA. When the sample was spiked with FXIa at
32.5 times the concentration present in normal specimens, the
amount of FXIa remaining in the sample after the removal process
was below the detection limits. Even when the sample was spikedchange chromatography (CM Hyper D).
/o spiked Pre-CEX w/Spiked d
/L) TGA b (IU/L) ELISA (mg/L) TGA (IU/L) ELISA (mg/L) TGA (IU/L)
42.2 4020.1 72837.4 21002.2 447861.4
<1.56 <0.31 <1.56 2.93 <1.56
95.3 99.4
N.C. N.C. N.C. 0.01 N.C.
ecimens.
process to remove thrombogenic factors (II, VII, IX, X, and XI) from
tp://dx.doi.org/10.1016/j.biologicals.2016.11.002
Fig. 5. Flow chart for the assessment of elimination of FXIa via CEX chromatography in the spiking study. In these two spiking studies, commercial FXIa was spiked in the in-
termediates (post virus inactivation (S/D)) of GC5101B to assess the ability of CEX chromatography to remove FXIa. IgG concentration: Pre-CEX 21.1 g/L, Post-CEX 10.4 g/L, spiked
FXI/FXIa concentration: 4.0 mg/mL, 21.0 mg/mL; 4.0 mg/mL: FXI/FXIa concentration in normal plasma, 21.0 mg/mL: FXIa concentration in cryopaste. These concentrations are 32.5
times and 169.9 times higher than those in normal specimens.
Table 2
Results of the TGA, Chromogenic FXIa assay, and NaPTT assay for FXIa in the ﬁnished Product of GC5101B.
Batch No.a TGA (mIU/mL) Chromogenic FXIa (mIU/mL) NaPTT (s)
01:05 Ratiob 01:10 Ratioc
1 <1.56 <0.16 267.6 1 265.3 1
2 <1.56 <0.16 265.45 1 258.55 0.97
3 <1.56 <0.16 270.7 1.02 262.05 0.98
4 <1.56 <0.16 273.45 1 266.5 0.97
5 <1.56 <0.16 265.15 0.97 263.55 0.96
6 <1.56 <0.16 266.9 1 257 0.96
7 <1.56 <0.16 268.7 0.98 265.3 0.97
8 <1.56 <0.16 270.15 0.99 263.85 0.96
9 <1.56 <0.16 264.3 0.97 262.1 0.96
Mean ± SD <1.56 <0.16 268.04 ± 3.0 0.99 ± 0.0 262.69 ± 3.2 0.97 ± 0.0
All samples were measured at least in duplicate.
a Data from nine batches after sterile ﬁltration andmaltose addition. Product release speciﬁcation is as per United States pharmacopeia (USP)'s test standard (the example of
standard): Protein concentration: 50.0 ± 0.3 g/L, molecular size distribution: monomer þ dimer > 90.0%, polymer  3.0%, anti-HBsAg:  0.5 IU/g IgG, anti-complimentary
activity: consumption of complement < 50%, PKA:  35 IU/mL 3% IgG, etc.).
b Ratio of clotting time of the sample diluted 5 times to the clotting time of the tris albumin buffer.
c Ratio of clotting time of the sample diluted 10 times to the clotting time of the tris albumin buffer.
D.H. Park et al. / Biologicals xxx (2016) 1e86with FXIa at 169.9 times the concentration present in normal
specimens, only a small amount of FXI/FXIa could be detected by
ELISA; however, by TGA, this amount was found to below the
detection limits (<1.56 mIU/mL). This result was the same regard-
less of whether the starting material or the spiked samples were
tested.
Thus, we successfully removed the coagulation factors FII, FVII,
FIX, and FX through cold ethanol precipitation and removed FXIaPlease cite this article in press as: Park DH, et al., A new manufacturing
intravenous immunoglobulin gamma preparations, Biologicals (2016), htusing chromatography. The use of our method can help ensure the
safety of pharmaceutical preparations and by removing FXIa levels
to below the detection limit, minimize or even eliminate the risk of
thromboembolic events. When consecutive nine batches (on
commercial scale) were produced using the new manufacturing
process and the procoagulant activity was measured, a very low
standard deviation (<5.0%) was found and thus we predict that the
risk of thromboembolic events will be low. This conﬁrmed that theprocess to remove thrombogenic factors (II, VII, IX, X, and XI) from
tp://dx.doi.org/10.1016/j.biologicals.2016.11.002
D.H. Park et al. / Biologicals xxx (2016) 1e8 7new puriﬁcation process was robust and that it could ensure the
safety of the pharmaceutical preparation.
Several previous studies have attempted to correlate the con-
centration of coagulant factors in IVIG with the risk of thrombo-
embolic events. For example, Roemisch et al. demonstrated that
IVIG samples containing2 mIU/mL did not provoke any thrombus
formation using the Wessler test [28]. Funk et al. demonstrated the
correlation between NaPTT and thromboembolic events in com-
mercial IVIG batches for a period of 6 years [29]. NaPTT time >200 s
and a NaPTT ratio >0.8 in IVIG resulted in low thromboembolic
event rates. In our study, TGA and NaPTT data from GC5101B were
found to be below 2 mIU/mL (<1.56 mIU/mL) and over 200 s
(262.69 ± 3.2). However, our results are difﬁcult to directly compare
with the previous studies as we have used different test and
standard materials to determine FXIa activity. Additional in vivo
assays such as the Wessler test would be necessary to demonstrate
the safety of the preparations more precisely.
Our ﬁndings indicate that the risk of thromboembolic events
that can occur with the use of pharmaceutical preparations may be
predicted by measuring the procoagulant activities using assays to
evaluate thrombin generation, FXIa chromogenic activity, Pre-
kallikrein activator activity, kallikrein activity, and NaPTT. For this
reason, we recommend that the same methods be used to deter-
mine procoagulant activity to obtain comparable results. Then, by
measuring the correlation between the results of the Wessler test
and the procoagulant activity, relatively simple in vitro assay re-
sults would be expected to be able to efﬁciently determine the
safety of the product.
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